Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Brigatinib

FDA-approved product (tablet, oral), marketed as Alunbrig.

Registered studies
48
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Brigatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

48registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Brigatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-4.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Brigatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Personalized DC Vaccines in Non Small Cell Lung Cancer

    NCT05195619 · start 2022-03-22

    Registered record
    Registry ID
    NCT05195619
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine); Low dose cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2022-03-22
    Completion
    2027-06
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionAutologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine); Low dose cyclophosphamide
    PhasePhase 1
    Registry statusActive not recruiting

  • ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

    NCT05014464 · start 2021-11-13

    Registered record
    Registry ID
    NCT05014464
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-11-13
    Completion
    2027-08-08
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionCrizotinib
    PhasePhase 2
    Registry statusRecruiting

  • Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

    NCT05100069 · start 2021-11-01

    Registered record
    Registry ID
    NCT05100069
    Conditions
    Non-small Cell Lung Cancer (NSCLC)
    Interventions
    Brigatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-11-01
    Completion
    2030-09-30
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer (NSCLC)
    InterventionBrigatinib
    PhaseNot recorded
    Registry statusRecruiting

  • Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)

    NCT06234579 · start 2021-07-12

    Registered record
    Registry ID
    NCT06234579
    Conditions
    ALK Gene Mutation; NSCLC Stage IV; ALK Sensitizing Mutation
    Interventions
    Biopsy (tissue or liquid)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-07-12
    Completion
    2026-07-31
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK Gene Mutation; NSCLC Stage IV; ALK Sensitizing Mutation
    InterventionBiopsy (tissue or liquid)
    PhaseNot recorded
    Registry statusUnknown

  • Retrospective, Observational, Multi-center Study Evaluating the Efficacy and Tolerance of Brigatinib in the Management of Rearranged CBNPC ROS1

    NCT04718012 · start 2021-03-17

    Registered record
    Registry ID
    NCT04718012
    Conditions
    Lung Cancer ROS Translocated
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-03-17
    Completion
    2021-10-17
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer ROS Translocated
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)

    NCT04887519 · start 2020-12-30

    Registered record
    Registry ID
    NCT04887519
    Conditions
    Carcinoma, Non-Small-Cell Lung; Anaplastic Lymphoma Kinase
    Interventions
    No Intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-12-30
    Completion
    2023-03-31
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung; Anaplastic Lymphoma Kinase
    InterventionNo Intervention
    PhaseNot recorded
    Registry statusCompleted

  • Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

    NCT04647110 · start 2020-12-14

    Registered record
    Registry ID
    NCT04647110
    Conditions
    ALK-positive NSCLC
    Interventions
    crizotinib; alectinib; brigatinib; ceritinib; lorlatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-12-14
    Completion
    2021-03-15
    Enrolment
    549

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-positive NSCLC
    Interventioncrizotinib; alectinib; brigatinib; ceritinib +1 more
    PhaseNot recorded
    Registry statusCompleted

  • Brigatinib Before Brain Irradiation Trial (B3i Trial)

    NCT04634110 · start 2020-11-17

    Registered record
    Registry ID
    NCT04634110
    Conditions
    Brain Metastases; Lung Cancer
    Interventions
    Brigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-11-17
    Completion
    2022-04-14
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Metastases; Lung Cancer
    InterventionBrigatinib
    PhasePhase 2
    Registry statusTerminated

  • The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

    NCT04591431 · start 2020-10-07

    Registered record
    Registry ID
    NCT04591431
    Conditions
    Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    Interventions
    Erlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab; Lapatinib; Everolimus; Vemurafenib; Cobimetinib; Alectinib; Brigatinib; Palbociclib; Ponatinib; Vismogedib; Itacitinib; Ipatasertib; Entrectinib; Atezolizumab; Nivolumab; Ipilimumab; Pemigatinib; Oncology Drugs; Pralsetinib; Selpercatinib; Talazoparib; Tepotinib; Alpelisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-10-07
    Completion
    2025-06
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    InterventionErlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab +22 more
    PhasePhase 2
    Registry statusUnknown

  • Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

    NCT04260009 · start 2020-09-01

    Registered record
    Registry ID
    NCT04260009
    Conditions
    Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma; Inflammatory Myofibroblastic Tumors; Solid Tumors
    Interventions
    Brigatinib; Brigatinib AAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2020-09-01
    Completion
    2025-09-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma; Inflammatory Myofibroblastic Tumors; Solid Tumors
    InterventionBrigatinib; Brigatinib AAF
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

    NCT04374305 · start 2020-06-20

    Registered record
    Registry ID
    NCT04374305
    Conditions
    Neurofibromatosis Type 2; Vestibular Schwannoma; Non-vestibular Schwannoma; Meningioma; Ependymoma
    Interventions
    Brigatinib; Neratinib; Retifanlimab; Bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-06-20
    Completion
    2030-12-01
    Enrolment
    109

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurofibromatosis Type 2; Vestibular Schwannoma; Non-vestibular Schwannoma; Meningioma +1 more
    InterventionBrigatinib; Neratinib; Retifanlimab; Bevacizumab
    PhasePhase 2
    Registry statusRecruiting

  • Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays

    NCT04074993 · start 2020-05-15

    Registered record
    Registry ID
    NCT04074993
    Conditions
    Non Small Cell Lung Cancer
    Interventions
    Brigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-05-15
    Completion
    2025-03-31
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer
    InterventionBrigatinib
    PhasePhase 2
    Registry statusUnknown

  • Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

    NCT04223596 · start 2020-05-04

    Registered record
    Registry ID
    NCT04223596
    Conditions
    Lung Cancer; NSCLC; NSCLC Stage IIIB; NSCLC Stage IV
    Interventions
    Brigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-05-04
    Completion
    2026-12-30
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; NSCLC; NSCLC Stage IIIB; NSCLC Stage IV
    InterventionBrigatinib
    PhasePhase 2
    Registry statusActive not recruiting

  • Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

    NCT04322890 · start 2020-04-16

    Registered record
    Registry ID
    NCT04322890
    Conditions
    Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation; MET Gene Mutation
    Interventions
    Osimertinib; Alectinib 150 MG; Crizotinib 250 MG; Savolitinib, Crizotinib.; Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-04-16
    Completion
    2027-12-24
    Enrolment
    6,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation +1 more
    InterventionOsimertinib; Alectinib 150 MG; Crizotinib 250 MG; Savolitinib, Crizotinib. +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

    NCT04318938 · start 2020-03-30

    Registered record
    Registry ID
    NCT04318938
    Conditions
    NSCLC
    Interventions
    Brigatinib; Tyrosine kinase inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-03-30
    Completion
    2026-05-30
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC
    InterventionBrigatinib; Tyrosine kinase inhibitor
    PhasePhase 2
    Registry statusCompleted